Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital marketing executive

- PMLiVE

NICE recommends three tumour profiling tests for early breast cancer patients

Breast cancer is the most common cancer in the UK, affecting more than 55,000 people every year

- PMLiVE

Study reveals third COVID-19 vaccine dose improves defence in vulnerable patients

Approximately 90% of patients who received a third dose developed significant levels of antibodies

- PMLiVE

Sanofi and Novavax announce COVID-19 vaccine licensing agreement worth over $1.2bn

The deal gives Sanofi a licence to use Novavax’s COVID-19 vaccine in combination with its own flu vaccines

- PMLiVE

Shionogi gains rights to Maze’s investigational Pompe disease therapy for $150m upfront

The inherited disorder is estimated to affect about one in 40,000 people in the US

- PMLiVE

ICR researchers reveal key driver of PARP inhibitor resistance in advanced breast cancer

Currently the most common cancer in the UK, breast cancer affects over 55,000 people annually

- PMLiVE

Researchers develop microneedle patch to reverse hair loss caused by alopecia areata

The autoimmune skin condition currently affects more than six million people in the US

Boosting Engagement with Fun: Asynchronous Touchpoints – Impetus InSite Tips for Optimizing Asynchronous Virtual Meetings

Unlock the secret to keeping participants engaged in longer asynchronous touchpoints with our sixth tip. Learn how integrating elements of fun can refresh focus and enhance interaction in virtual settings.

Impetus Digital

- PMLiVE

UK government launches five-year national action plan for antimicrobial resistance

It is estimated that 1.27 million global deaths in 2019 were caused by antibiotic-resistant infections

- PMLiVE

AstraZeneca/Sanofi reveal promising real-world data for Beyfortus in infant RSV

The treatment reduced RSV hospitalisations by 82% in infants under six months during the 2023 to 2024 RSV season

- PMLiVE

LEO Pharma shares positive phase 3 results for Enstilar in stable plaque psoriasis

Up to 3% of the global population has some form of psoriasis, a chronic inflammatory condition

- PMLiVE

Researchers’ new vaccine technology shows efficacy against broad range of coronaviruses

The vaccine provided protection against coronaviruses that have not yet emerged

- PMLiVE

Sobi’s Aspaveli receives expanded EC approval for rare blood disorder PNH

The C3 therapy can now be used as a first-line treatment for paroxysmal nocturnal haemoglobinuria

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links